Antimüllerian hormone predicts cumulative live birth rate in women with diminished ovarian reserve

A strong association exists between serum antimüllerian hormone (AMH) and cumulative live birth rate (CLBR) in women with diminished ovarian reserve (DOR) undergoing assisted reproductive technology, independent of age, suggests a recent study.

“The addition of AMH to current age-based prognostication counseling particularly in women with DOR would provide more informative and personalized CLBR prediction prior to assisted reproductive technology,” the investigators said.

A team of researchers investigated the relationship between serum AMH and CLBR among women with DOR undergoing assisted reproductive technology by performing a retrospective analysis of Society for Assisted Reproductive Technology Clinic Outcome Reporting System database from 2014 to 2016.

The researchers analysed a total of 34,540 (25.9 percent) index retrieval cycles (IRCs) of women with AMH <1 ng/mL out of 133,442 autologous IRCs. Cycles with preimplantation genetic testing or egg/embryo banking were not included in the analysis.

In addition, the researchers stratified data according to AMH and performed age and regression analysis of AMH and CLBR for each age stratum.

In multiple logistic regression analysis, AMH was found to be independently correlated with CLBR (odds ratio, 1.39, 95 percent confidence interval, 1.18–1.64). Serum AMH showed a strong association with the number of oocytes retrieved, embryos cryopreserved, mean number of cumulative embryos transferred, and percentage of cycles that had an embryo transfer.

In linear regression analysis, AMH was highly predictive of CLBR in each age stratum.